Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010

Similar documents
Addiction Recovery Treatment Services (ARTS): Billing Best Practices. December 2017

NIA Magellan 1 Radiation Oncology Solution Provider Training

Harvard Pilgrim Spine Management Provider Training

Blue Cross Blue Shield of Nebraska Spine Management Provider Training. Provider Training Presented by Leta Genasci

New patients approved for the Novo Nordisk PAP may only be eligible for insulin vials. For a full list of available products, please visit:

Medi Cal Managed Care. Melissa Lamer, PharmD, BCPP July 31 st, 2014

NIA Magellan 1 Medical Specialty Solutions

National Drug Code Directory

Overview. Provider Enrollment Requirements Member Eligibility Hearing Services Authorization and Billing Additional Information

Clinical Policy: Atezolizumab (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17

FDA Approved Indication(s) Firmagon is indicated for treatment of advanced prostate cancer.

Coventry Health Care of Georgia, Inc.

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Texas Vendor Drug Program Specialty Drug List Process. February 2019

SODIUM BICARBONATE National Drug Code Directory

Reimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.

See Important Reminder at the end of this policy for important regulatory and legal information.

PHARMACY COMPLIANCE RISK AREAS FOR 2014

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:

Clinical Policy: Trabectedin (Yondelis) Reference Number: CP.PHAR.204 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Aflibercept (Eylea) Reference Number: CP.PHAR.184

Reimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.

National Drug Code Directory

Pharmaceutical Management Medicaid 2019

SANOFI PASTEUR INFLUENZA VACCINE PRESENTATIONS CODING AND BILLING CHECKLIST

DIVALPROEX SODIUM National Drug Code Directory

Table 1 Healthcare Common Procedure Coding System Codes Effective December 1, 2009

Clinical Policy: Eribulin Mesylate (Halaven) Reference Number: CP.PHAR.318

KETAMINE HYDROCHLORIDE National Drug Code Directory

Clinical Policy: Topotecan (Hycamtin) Reference Number: CP.PHAR.64 Effective Date: Last Review Date: Line of Business: Medicaid, HIM

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Dabrafenib (Tafinlar) Reference Number: CP.PHAR.239 Effective Date: 07/16 Last Review Date: 07/17 Line of Business: Medicaid

Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295

In its written comments on our draft report, CMS concurred with our recommendation.

FLUZONE INTRADERMAL QUADRIVALENT National Drug Code Directory

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Amy Larrick Chavez-Valdez, Director, Medicare Drug Benefit and C & D Data Group

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119

See Important Reminder at the end of this policy for important regulatory and legal information.

LOUISIANA MEDICAID PROGRAM ISSUED: 02/01/12 REPLACED: 02/01/94 CHAPTER 5: PROFESSIONAL SERVICES SECTION 5.1: COVERED SERVICES PAGE(S) 5

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16

See Important Reminder at the end of this policy for important regulatory and legal information.

RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS

WEBINAR 1 CODING FOR FLUZONE VACCINATION CODING AND BILLING FOR VACCINATION WITH FLUZONE, INFLUENZA VACCINES CRACKING THE CODES: UPDATED for

Uphold LITE Vaginal Support System 2015 Coding & Quick Reference Guide

Standards for Professional Conduct In The Practice of Dentistry

MORPHINE SULFATE National Drug Code Directory

Clinical Policy: Pralatrexate (Folotyn) Reference Number: CP.PHAR.313 Effective Date: Last Review Date: Line of Business: Medicaid

PRODUCT DISTRIBUTION GUIDE SELECT IMPORTANT SAFETY INFORMATION INDICATION. Infusion-Related Reactions

Part D PDE Data and the Opioid Epidemic

MYCAMINE National Drug Code Directory

Medicare Part D Overutilization Monitoring System

See Important Reminder at the end of this policy for important regulatory and legal information.

2015 Facility and Physician Billing Guide Heart Valve Technologies

DEXAMETHASONE SODIUM PHOSPHATE National Drug Code Directory

FLUCELVAX QUADRIVALENT (PREFILLED SYRINGE) National Drug Code Directory

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE National Drug Code Directory

Pharmacy Audit Recovery Guidelines

Clinical Policy: Ferric Carboxymaltose (Injectafer) Reference Number: CP.PHAR.234

Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date:

DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f

See Important Reminder at the end of this policy for important regulatory and legal information.

HAVRIX National Drug Code Directory

Ultrasound Reimbursement Information for Anesthesiology 1

October 2015 news bulletin

Changes to the Eighth Edition

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Obinutuzumab (Gazyva) Reference Number: CP.PHAR.305 Effective Date: Last Review Date: Line of Business: Medicaid

Virginia s Behavioral Health Services Administrator: Magellan Behavioral Health, Inc Promoting Wellness and Recovery

Clinical Policy: Iron Sucrose (Venofer) Reference Number: CP.PHAR.167

Clinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264

See Important Reminder at the end of this policy for important regulatory and legal information.

POTASSIUM CITRATE CITRIC ACID CRYSTALS National Drug Code Directory

Clinical Policy: Darbepoetin alfa (Aranesp) Reference Number: ERX.SPMN.13

General Providers. Tamper-Resistant Prescription Requirements

OVERVIEW OF THE 2017 VFD PROGRAM

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE National Drug Code Directory

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90

Billing & Coding Guide

Surgical Preparation Codes for Skin Replacement Surgery** Hospital Outpatient/Ambulatory Surgical Center Setting

Clinical Policy: DNA Analysis of Stool to Screen for Colorectal Cancer

2009 Pain Coding Update and Pain Industry Business Trends

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327

CITRANATAL DHA National Drug Code Directory

LIPITOR AND YOU HELPFUL INFORMATION FOR UNDERSTANDING CHOLESTEROL AND RISKS

Thyrogen (thyrotropin alfa for injection) Billing and Coding Guide

RETIRED. Maximum Drug Dose Policy

A newsletter for Molina Healthcare Provider Networks. Fall 2018

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Issues for Part D Compliance

Transcription:

Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010

Physician-Administered Drugs Physician-administered drugs are drugs, other than vaccines, that are covered under section 1927(k)(2) of the Social Security Act and are typically administered by a medical professional in a physician s office or other outpatient clinical setting. Reimbursement for physician-administered drugs is allowed only if the drug qualifies for rebate in accordance with 42 USC 1396r-8. The injection must be reasonable and medically necessary for diagnosis or effective treatment of a specific illness or injury based on accepted standards of medical practice. Therapeutic injections should be utilized only if equally effective oral medications cannot be prescribed without significant or increased side effects. 2

Accessing the PIDL The PIDL is located on the Department for Medicaid Services website: http://chfs.ky.gov/dms/fee The link is also located on the Magellan Rx Management website: https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml under the tab labeled Drug Info The PIDL will be updated on a regular basis, at least quarterly. 3

Billing Instructions

Billing Your Claims Drugs that are covered through the Physician s Drug Program will be listed on the PIDL and must be billed through the medical benefit on a CMS-1500 claim form or the electronic 837P. Drugs that are NOT covered through the Physician s Drug Program may be covered through the Pharmacy Program. Drugs covered through the Pharmacy program must be obtained by prescription and billed through the online point-of-sale (POS) system at the pharmacy. 5

Billing Instructions (BIs) The online billing instructions are located on the Department for Medicaid Services website: http://chfs.ky.gov/dms/provider.htm The link is also located on the Magellan Rx Management website: https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml under the tab labeled Drug Info 6

National Drug Code (NDC)

The Federal Deficit Reduction Act of 2005 The Federal Deficit Reduction Act of 2005 (DRA) requires State Medicaid Programs to collect rebates from participating drug manufacturers for physicianadministered or dispensed drugs. In order to collect these rebates, states must collect the National Drug Codes (NDC) for the physician-administered drugs. This requirement also applies to Medicare crossover claims. 8

National Drug Codes (NDC) The National Drug Code (NDC) is a unique product identifier for drugs. Drug products are identified and reported to the Food and Drug Administration (FDA) using the NDC identifier. An NDC consists of 10 digits separated into 3 sections by hyphens. The NDC is found on the drug container (e.g., vial, bottle, or tube). The NDC submitted to Medicaid MUST be the actual NDC number on the package or container from which the medication was administered. It is considered a fraudulent billing practice to bill using an NDC other than the one administered to the patient. 9

National Drug Codes (continued ) The first 4 or 5 digit segment is the drug labeler code. A labeler is an entity that manufactures, repacks or distributes a drug product. This code is assigned by the FDA. The next 3 or 4 digit segment identifies the product and the specific strength, dosage form, and formulation. The last 1 or 2 digit segment is the package form and size. Examples: 1234-5678-90 12345-678-90 12345-6789-0 10

National Drug Codes (continued ) Each NDC-coded product package bears a barcode with a Universal Product Code that begins with a 3 (UPC-A) or 03 (EAN-03). The remainder of the number is the 10 NDC digits, plus the check digit. The Centers for Medicare and Medicaid Services (CMS) has created an 11-digit NDC derivative. Leading 0 s must be added to each segment resulting in a 5-4-2 configuration. Conversion Examples: 01234-5678-90 12345-0678-90 12345-6789-00 11

How to Determine if the Product is a Drug? The following items will help identify whether or not a product is a drug: NDC Found on the drug container (e.g., vial, bottle, or tube). Lot and Expiration Date All drugs have both a lot number and an expiration date located on the drug or package. Legend Refers to statements such as, Caution: Federal law prohibits dispensing without prescription, Rx only or similar wording. All prescription drugs have these types of statements. 12

Additional Resources

How to Determine if the Product is a Drug? Participating Labelers CMS maintains the list of labelers on the following website: http://www.cms.hhs.gov/medicaiddrugrebateprogram/10_drugcomcontactinfo.asp Provider Notices For the Department for Medicaid Services, please refer to the following website: http://chfs.ky.gov/dms/physician.htm For Magellan Rx Management, please refer to the following website: https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml under the tab labeled, Notices Conversion Factors For a list of J Code to NDC conversion factors please refer to the following website: https://www.dmepdac.com/crosswalk/index.html HCPCS List For a list of HCPCS codes please refer to the following website: http://www.cms.hhs.gov/hcpcsreleasecodesets/anhcpcs/list.asp 14

Questions

Contact Information If you have questions regarding the submission of a claim, procedure code(s), remittance advice, and/or payment Contact a HP (formerly EDS) Provider Representative at 800-807-1232 If you have questions relating to rebates for physician administered drugs or NDC numbers Contact Magellan Rx Management at 314-387-4793. 16

Confidentiality Statement By receipt of this presentation, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, or distributed to or disclosed to others at any time without the prior written consent of Magellan Health, Inc. The information contained in this presentation is intended for educational purposes only and is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment. *If the presentation includes legal information (e.g., an explanation of parity or HIPAA), add this: The information contained in this presentation is intended for educational purposes only and should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors. 17

Thank You